Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14836350 | 1.00 | OPRM1 (0.55) | OPRM1SIGMAR1CYP3A4HSD17B10MC4R | |
| SCHEMBL18458358 | 0.95 | OPRM1 (0.56) | OPRM1SIGMAR1CYP3A4HSD17B10MC4R | |
| SCHEMBL22441511 | 0.92 | OPRM1 (0.59) | OPRM1SIGMAR1CYP3A4HSD17B10MC4R | |
| SCHEMBL21337177 | 0.90 | OPRM1 (0.46) | OPRM1SIGMAR1CYP3A4HSD17B10TMEM97 | |
| SCHEMBL4031096 | 0.88 | OPRM1 (0.58) | OPRM1SIGMAR1CYP3A4HSD17B10HRH3 | |
| SCHEMBL2335642 | 0.87 | OPRM1 (0.60) | OPRM1SIGMAR1CYP3A4HSD17B10TSHR | |
| SCHEMBL18458363 | 0.86 | OPRM1 (0.52) | OPRM1SIGMAR1CYP3A4HSD17B10MC4R | |
| SCHEMBL3523156 | 0.86 | OPRM1 (0.52) | OPRM1SIGMAR1CYP3A4HSD17B10MC4R | |
| SCHEMBL14279621 | 0.86 | MC4R (0.59) | OPRM1SIGMAR1CYP3A4HSD17B10MC4R | |
| SCHEMBL20482001 | 0.84 | MC4R (0.50) | OPRM1SIGMAR1CYP3A4HSD17B10MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-01 | — | — | US | disclosed |
| EP-3328853-B1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-09-11 | — | — | EP | disclosed |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| WO-2017016669-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-02-02 | — | — | WO | disclosed |
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2575815-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-1150970-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Sanofi-Aventis (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000047572-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 2000-08-17 | — | — | WO | disclosed |
| EP-0459387-B1 | Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit | ABBOTT LAB (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5407834-A | Monoclonal antibody which binds phencyclidine and metabolites, raised against specified immunogen, lacking specifed cross reactivity | ABBOTT LABORATORIES (US) | 1995-04-18 | — | — | US | disclosed |
| US-5221629-A | Fluorescence polarization assay | ABBOTT LABORATORIES (US) | 1993-06-22 | — | — | US | disclosed |
| US-5155212-A | Substituted phencyclidine compound linked to polyamino acid | ABBOTT LABORATORIES (US) | 1992-10-13 | — | — | US | disclosed |
| US-5124457-A | Fluorescein moiety tracer; fluorescence polarization assay | ABBOTT LABORATORIES (US) | 1992-06-23 | — | — | US | disclosed |
| EP-0459387-A2 | Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit | ABBOTT LABORATORIES (US) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885SIGMAR1 5/4885CYP3A4 890/4885 |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885SIGMAR1 5/4885CYP3A4 890/4885 |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC6A5, SLC7A1, AGXT | OPRM1 552/4885SIGMAR1 426/4885CYP3A4 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.